Brief: Xintela Says Its Clinical Phase I/IIa Study In Patients With Knee Osteoarthritis Is Progressing Very Well
30/08/2023 07:10
Aug 30 (Reuters) - Xintela AB XINT.ST :
* OUR CLINICAL PHASE I/IIA STUDY IN PATIENTS WITH KNEE
OSTEOARTHRITIS IN AUSTRALIA IS PROGRESSING VERY WELL
Source text for Eikon: ID:nMFN2YybC2
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects